Diabetes Clinical Trials in Arizona

Showing 221-240 of 289 trials

PGC-1 and Mitochondrial Dysfunction in Diabetes

NCT01724515

The purpose of this study is determine if you have too much fat in your body that it will decrease the conversion of food energy into energy that your body can use.

DiabetesObese

Mayo Clinic16 participantsStarted Sep 2012

Scottsdale, Arizona, United States

COMPLETEDPHASE331 miles

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

NCT00039026

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.

Diabetes Mellitus, Non-Insulin-Dependent

AstraZeneca377 participantsStarted Feb 2002

Anniston, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +123 more locations

PreviousPage 12 of 15Next

PGC-1 and Mitochondrial Dysfunction in Diabetes

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Diabetes Trials in Other Cities

Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Dapagliflozin DPPIV Inhibitor add-on Study

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies

Other Conditions in Arizona